1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First

 
• By Francesca Bruce

Sage Therapeutics is on track to deliver the first ever drug to be indicated for postpartum depression. The company discusses plans for launch and whether or not it wants to partner.

SAGE Therapeutics Inc.'s Sage-547 is on track to become the first ever pharmaceutical indicated for postpartum depression. It has won PRIME designation from the European Medicines Agency and Breakthrough Therapy Designation for the treatment of PPD from the US FDA. Jeff Jonas, the company's CEO, speaks to Scrip about what when it expects to launch, what it wants from a partner and what it might charge.

Sage has announced it has won PRIME designation from the European Medicines Agency. The PRIME program is aimed at accelerating the regulatory process for promising investigational medicines that could offer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapy Areas

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.